ARTICLE | Market Access
With setbacks mounting and NCD looming, Biogen halves Aduhelm cost
Discount raises questions about impact on Aduhelm uptake, landscape for Lilly’s launch
December 21, 2021 2:13 AM UTC
Days after a negative CHMP opinion and a few weeks away from CMS’s draft coverage determination, Biogen announced it was cutting Aduhelm’s controversial $56,000 price tag in half. While it’s unclear to what extent the discount will boost Aduhelm uptake, it is bound to change the benchmark for Lilly’s next-in-line β-amyloid mAb, which is expected to launch 2H22.
On Monday, Biogen Inc. (NASDAQ:BIIB) said it would reduce the wholesale acquisition cost of Aduhelm aducanumab-avwa by about 50% to $28,200 per year for a patient of average weight, with the goal of lowering out-of-pocket costs for patients and financial consequences for the U.S. healthcare system. ...